S&P 500 Futures
(-0.08%) 5 304.25 points
Dow J Futures
(-0.09%) 40 140 points
Nasdaq Futures
(-0.05%) 18 465 points
Oil
(-0.07%) $83.11
Gas
(-0.62%) $1.752
Gold
(0.73%) $2 254.80
Silver
(0.74%) $25.10
Platinum
(0.21%) $923.00
USD/EUR
(0.10%) $0.927
USD/NOK
(0.10%) $10.85
USD/GBP
(0.07%) $0.793
USD/RUB
(-0.06%) $92.52

Realtime updates for Corbus Pharmaceuticals [CRBP]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BUY
100.00%
return 12.01%
SELL
0.00%
return 24.78%
Last Updated28 Mar 2024 @ 16:00

10.32% $ 39.24

SELL 63079 min ago

@ $23.69

Issued: 14 Feb 2024 @ 09:41


Return: 65.64%


Previous signal: Feb 13 - 09:30


Previous signal: Buy


Return: 11.15 %

Live Chart Being Loaded With Signals

Commentary (28 Mar 2024 @ 16:00):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302
Profile picture for Corbus Pharmaceuticals Holdings Inc

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases...

Stats
Today's Volume 234 856
Average Volume 945 380
Market Cap 411.75M
EPS $0 ( 2024-03-12 )
Next earnings date ( $-1.090 ) 2024-05-14
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -3.81
ATR14 $0.161 (0.41%)
Insider Trading
Date Person Action Amount type
2024-03-08 Cormorant Asset Management, Lp Buy 8 862 Common Stock
2024-03-08 Cormorant Asset Management, Lp Buy 156 597 Common Stock
2024-03-08 Cormorant Asset Management, Lp Buy 61 668 Common Stock
2024-03-08 Cormorant Asset Management, Lp Buy 18 548 Common Stock
2024-03-08 Cormorant Asset Management, Lp Buy 24 983 Common Stock
INSIDER POWER
99.67
Last 95 transactions
Buy: 14 121 102 | Sell: 363 874

Volume Correlation

Long: -0.19 (neutral)
Short: 0.92 (very strong)
Signal:(57.442) Expect same movement, but be aware

Corbus Pharmaceuticals Correlation

10 Most Positive Correlations
VKTX0.923
BLPH0.919
CHMA0.904
BTF0.903
ALBO0.902
SUMO0.901
CMPI0.901
NVCN0.899
IMRX0.885
NLTX0.885
10 Most Negative Correlations
MSBI-0.949
BWFG-0.948
NFBK-0.946
CNOB-0.944
ONB-0.944
PFBC-0.944
FBIZ-0.943
PGC-0.943
BCBP-0.941
WSFS-0.941

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Corbus Pharmaceuticals Correlation - Currency/Commodity

The country flag 0.24
( neutral )
The country flag 0.30
( neutral )
The country flag 0.00
( neutral )
The country flag 0.07
( neutral )
The country flag -0.25
( neutral )
The country flag 0.12
( neutral )

Corbus Pharmaceuticals Financials

Annual 2023
Revenue: $0
Gross Profit: $-641 000 (0.00 %)
EPS: $-10.31
Q4 2023
Revenue: $1.35M
Gross Profit: $1.20M (89.04 %)
EPS: $-1.810
Q3 2023
Revenue: $0
Gross Profit: $-152 809 (0.00 %)
EPS: $-2.27
Q2 2023
Revenue: $0
Gross Profit: $-158 343 (0.00 %)
EPS: $-2.05

Financial Reports:

No articles found.

Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators